multiple myeloma

Pharma

FDA 'proactively' awards J&J a national priority review voucher

The FDA granted the CNPV to J&J's combination of Tecvayli and Darzalex in multiple myeloma just a few days after a detailed phase 3 data presentation.

Angus Liu Dec 15, 2025 12:33pm

ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma

Dec 9, 2025 7:30am

ASH: Regeneron eyes simpler regimens to grow bispecifics' reach

Dec 8, 2025 8:00am

J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T

Nov 12, 2025 11:36am

FDA OKs Darzalex as 1st drug for smoldering multiple myeloma

Nov 6, 2025 4:27pm

GSK gets FDA green light for long-awaited Blenrep comeback

Oct 24, 2025 8:02am